CAR-T Meeting 2026 | What makes nursing in cellular therapy different from traditional oncology care?
Mairéad Ní Chonghaile, RGN, BNS, MSc, St James’s Hospital, Dublin, Ireland, briefly discusses how nursing in cellular therapy differs from traditional oncology nursing, highlighting the importance of nurses in the field promptly recognizing side effects such as immune effector cell-associated neurotoxicity syndrome (ICANS) and cytokine release syndrome (CRS). Ms Ní Chonghaile also emphasizes the importance of educating oncology nurses in traditional care settings about these side effects as therapies such as bispecifics become more widely used. This interview took place at the EBMT-EHA 8th European CAR T-cell Meeting, held in Palma de Mallorca, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think what is different, and it’s the same way as maybe whereas transplant nursing is different and hematology nursing is different from oncology nursing, is that there’s that mix of hyper-acute intensive care element and traditional oncology nursing mixed in. It’s the recognition of, as we’ve seen so often throughout this meeting, the prompt and early recognition of side effects, particularly the new ones with ICANS and CRS, that are really important...
I think what is different, and it’s the same way as maybe whereas transplant nursing is different and hematology nursing is different from oncology nursing, is that there’s that mix of hyper-acute intensive care element and traditional oncology nursing mixed in. It’s the recognition of, as we’ve seen so often throughout this meeting, the prompt and early recognition of side effects, particularly the new ones with ICANS and CRS, that are really important. And also, I think we have a really important role in educating oncology nurses in traditional oncology care because the likes of the bispecifics coming into their areas of nursing is becoming really more important because the cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are coming through with some of the bispecifics and things like that, so it’s really important that that knowledge can be passed on. A lot of, an awful lot of oncology nurses, while very knowledgeable, need to know about the side effects and what the patient has gone through to be able to deliver care safely in their own centres.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
